Core Insights - iRhythm Technologies reported a record revenue of $186.7 million for Q2 2025, reflecting a 26.1% increase compared to $148.0 million in Q2 2024, driven by strong demand for Zio services and market penetration of Zio AT [4][8] - The company achieved a gross profit of $132.9 million, up 28.4% from $103.5 million in the same quarter last year, with a gross margin of 71.2%, an increase from 69.9% [5][8] - iRhythm's net loss narrowed to $14.2 million, or a diluted loss of $0.44 per share, compared to a net loss of $20.1 million, or a diluted loss of $0.65 per share in Q2 2024, attributed to revenue growth and operational efficiencies [7][8] Financial Performance - Revenue for Q2 2025 was $186.7 million, a 26.1% increase from $148.0 million in Q2 2024 [4][8] - Gross profit reached $132.9 million, a 28.4% increase from $103.5 million in the same period last year, with a gross margin of 71.2% [5][8] - Operating expenses for Q2 2025 were $151.6 million, up from $126.5 million in Q2 2024, with adjusted operating expenses at $145.2 million compared to $125.2 million [6][8] Strategic Developments - The company executed a strategic partnership with Lucem Health to enhance early identification of undiagnosed arrhythmias, leveraging AI for predictive and preventive care [8] - iRhythm's annual revenue guidance for 2025 has been increased to a range of $720 million to $730 million, with an expected adjusted EBITDA margin of approximately 8.0% to 8.5% [10][8] Cash Position - As of June 30, 2025, iRhythm reported unrestricted cash, cash equivalents, and marketable securities totaling $545.5 million [9][8]

Core Viewpoint - iRhythm Technologies, Inc. reported strong financial results for Q1 2025, with revenue growth exceeding 20% year-over-year, driven by increased demand for its Zio services and expansion into new markets, including Japan [3][4]. Financial Highlights - Revenue for Q1 2025 was $158.7 million, a 20.3% increase from $131.9 million in Q1 2024 [4][8]. - Gross profit for Q1 2025 was $109.2 million, up 24.8% from $87.5 million in Q1 2024, with a gross margin of 68.8%, an increase from 66.3% in the same period last year [5][8]. - Operating expenses for Q1 2025 were $141.8 million, compared to $125.7 million in Q1 2024, primarily due to funding innovation and serving a growing patient volume [6][8]. - The net loss for Q1 2025 was $30.7 million, or a diluted loss of $0.97 per share, an improvement from a net loss of $45.7 million, or a diluted loss of $1.47 per share, in Q1 2024 [7][8]. Operational Highlights - The company achieved a milestone of 10 million patient reports since its inception, indicating strong market penetration and demand for its services [3]. - iRhythm's recent commercial launch in Japan is part of its strategy to expand its global reach, now operating in six markets outside the U.S. [3][8]. - The company presented findings at ACC.25 showing that traditional Holter monitoring often misses actionable arrhythmias, highlighting the effectiveness of its Zio long-term continuous monitor [8]. Guidance and Future Outlook - iRhythm projects full-year 2025 revenue between $690 million to $700 million, with an adjusted EBITDA margin expected to range from approximately 7.5% to 8.5% [10][8]. - The company is optimistic about future growth driven by innovative value-based care accounts and increasing demand for Zio AT services in the U.S. and the U.K. [3][8].

Core Viewpoint - iRhythm Technologies, Inc. is actively participating in the Bank of America Securities 2025 Health Care Conference, showcasing its commitment to advancing digital health solutions [1][2]. Company Overview - iRhythm Technologies, Inc. is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease through the use of wearable biosensors and cloud-based data analytics [3]. - The company utilizes proprietary algorithms to transform data from millions of heartbeats into clinically actionable information, aiming to enhance patient care and health outcomes [3]. Event Participation - iRhythm's management is scheduled to present at the conference on May 13, 2025, at 3:40 p.m. Pacific Time, with a live and archived webcast available for interested parties [2].